obesity treatment with bariatric surgery vs glp-1 receptor agonists Drugs vs. Weight Loss Surgery vs. Medication:
Description
Front Endocrinol 13:945609
-(1).png?sfvrsn=c236e848_3)
A 2024 comprehensive review examined multiple GLP-1 studies and found consistent safety patterns across medications in this class
These dual agonists were found to reduce blood sugar and increase insulin secretion in mice, monkeys, and humans
As most discontinuations occurred during the rapid dose-escalation period of treatment, slower up-titration of dose may counter these
As a result, since 2008, the FDA has required all new drugs for glycemic control in T2DM patients to demonstrate cardiovascular safety
